Proximal femoral multiple myeloma pathological fractures, impending and actual fractures - a patient survival study.
Femur
Metastases
Multiple Myeloma
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
02
01
2024
accepted:
23
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
The femur is a common site for Multiple Myeloma (MM) involvement. This study explores the impact of preventive surgery for anticipated femoral pathological fractures (IFF), based on Mirels classification, versus treatment of pathological femur fracture (PFF) on MM patient mortality and morbidity. Retrospective cohort of 33 patients undergoing surgery due to femoral MM involvement (2004-2015), 18 patients with PFF, 15 patients with IFF, followed up until deceased or to July 2016. Demographic data, oncological, pathological, radiation, surgical reports, outpatient clinical records, and imaging studies were studied. Exclusion criteria included patients who had surgery at other medical centers. The mean age was 70.4 ± 13.6 and 62.6 ± 12.2 years (p = 0.1) in the PFF and the IFF cohorts, respectively, primarily women (55.6% and 46.7%, respectively). The average Mirels' score was 10.4 ± 1.2. Post-operative complications were observed in 25% of patients, with no difference between IFF & PFF. We did not find a difference in mortality between IFF and PFF cohorts (p = 0.59). The femur is commonly involved in MM. This study found that actual fractures, compared to imminent fractures, do not affect MM morbidity or mortality. Our study shows that proximal femoral MM behaves differently from proximal femoral metastatic disease regarding the impact of surgery on life span. Due to the fracture healing potential of MM, an IFF can probably be treated initially conservatively unless it progresses to an actual fracture needing surgery. Future, more extensive studies are required before revolutionizing the proximal femoral Multiple Myeloma-related involvement treatment paradigm.
Identifiants
pubmed: 39080587
doi: 10.1186/s12885-024-12681-0
pii: 10.1186/s12885-024-12681-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
917Informations de copyright
© 2024. The Author(s).
Références
Bickels J, Dadia S, Lidar ZJJ. Surgical management of metastatic bone disease. 2009;91(6):1503–16.
Haidukewych GJ. Metastatic disease around the hip: maintaining quality of life. J Bone Joint Surg Br. 2012;94(11_Supple_A):22–25.
Cowan AJ, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77.
Shortt CP, Carty F, Murray JG. The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma. in Seminars in musculoskeletal radiology. © Thieme Medical Publishers; 2010.
Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. in Mayo Clinic Proceedings. Elsevier; 2003.
Kyriakou C, et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer J. 2019;9(3):1–10.
Mirels H. Research, Metastatic Disease in Long Bones A Proposed Scoring System for Diagnosing Impending Pathologic Fractures. Clin Orthop Relat Res. 1989;249:256–64.
Angelini A, et al. Treatment of pathologic fractures of the proximal femur. Injury. 2018;49:S77–S83.
Mavrogenis AF, et al. Survival analysis of patients with femoral metastases. J Surg Oncol. 2012;105(2):135–41.
Melton III LJ, et al. Fracture risk with multiple myeloma: a population‐based study. J Bone Miner Res. 2005;20(3):487–93.
Lefaivre K, et al. Length of stay, mortality, morbidity and delay to surgery in hip fractures. J Bone Joint Surg Br. 2009;91(7):922–7.
Sanz-Reig J, et al. Prognostic factors and predictive model for in-hospital mortality following hip fractures in the elderly. Chin J Traumatol. 2018;21(3):163–9.
Zhang X, et al. The biology of aging and cancer: frailty, inflammation, and immunity. Cancer J. 2017;23(4):201–5.
Aunan JR, Cho WC, Søreide K. The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks. Aging Dis. 2017;8(5):628–42. https://doi.org/10.14336/ad.2017.0103 .
Boddapati V, et al. Risks and Complications After Arthroplasty for Pathological or Impending Pathological Fracture of the Hip. J Arthroplasty. 2021;36(6):2049–54.e5. https://doi.org/10.1016/j.arth.2021.02.004 .
Roux C, et al. Percutaneous Fixation of Impending Fracture of the Hip. Tech Vasc Interv Radiol. 2022;25(1):100802. https://doi.org/10.1016/j.tvir.2022.100802 .
Owen AR, et al. Outcomes of Intramedullary Nail Fixation for Metastatic Disease: Impending and Pathologic Fractures. Anticancer Res. 2022;42(2):919–22. https://doi.org/10.21873/anticanres.15550 .
Ristevski B, et al. Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg. 2009;52(4):302.
pubmed: 19680515
pmcid: 2724796
Aneja A, et al. Thromboembolic disease in patients with metastatic femoral lesions: A comparison between prophylactic fixation and fracture fixation. JBJS. 2017;99(4):315–23.
doi: 10.2106/JBJS.16.00023
Thorsteinsdottir S, et al. Fractures and survival in multiple myeloma: results from a population-based study. 2020;105(4):1067.
Malhotra K, et al. Successful nonsurgical treatment for highly unstable fracture subluxation of the spine secondary to myeloma. Spine J. 2016;16(8):e547–e551.
Gainor BJ, Buchert P. Fracture healing in metastatic bone disease. Clin Orthop Relat Res. 1983;178:297–302.
Wodajo F, Colman M, Getty P. AAOS Clinical Practice Guideline Summary: Treatment of Metastatic Carcinoma and Myeloma of the Femur. J Am Acad Orthop Surg. 2023;31(3):e118–e129.
Gendi K, Hennessy D, Heiner J. The burden of metastatic disease of the femur on the Medicare system. SpringerPlus. 2016;5(1):1916. https://doi.org/10.1186/s40064-016-3572-8 .
Ashford RU, Randall RL. Bone metastases: epidemiology and societal effect, in Metastatic Bone Disease. Springer; 2016. p. 3–11.
Axelrod D, Gazendam AM, Ghert M. The Surgical Management of Proximal Femoral Metastases: A Narrative Review. Curr Oncol. 2021;28(5):3748–57.
Philipp TC, et al. Is there an association between prophylactic femur stabilization and survival in patients with metastatic bone disease? Clin Orthop Relat Res. 2020;478(3):540.
Piccioli A, et al. Intramedullary nailing for treatment of pathologic femoral fractures due to metastases. Injury. 2014;45(2):412–7.
Ratasvuori M, et al. Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. Surg Oncol. 2013;22(2):132–8.
doi: 10.1016/j.suronc.2013.02.008
pubmed: 23562148
Harrington KD. Orthopaedic management of metastatic bone disease. Mosby Incorporated; 1988.
Jonas SC, et al. Current orthopaedic management of bony metastases in the proximal third of the femur. Hip Int. 2017;27(1):1–7.
Padala SA, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3.
Brenner H, Gondos A, Pulte DJB. Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010. Blood. 2008;112(11):2368.